TY - JOUR
T1 - Tumor lactic acid
T2 - a potential target for cancer therapy
AU - Byun, Jun Kyu
N1 - Publisher Copyright:
© 2023, The Pharmaceutical Society of Korea.
PY - 2023/2
Y1 - 2023/2
N2 - Tumor development is influenced by circulating metabolites and most tumors are exposed to substantially elevated levels of lactic acid and low levels of nutrients, such as glucose and glutamine. Tumor-derived lactic acid, the major circulating carbon metabolite, regulates energy metabolism and cancer cell signaling pathways, while also acting as an energy source and signaling molecule. Recent studies have yielded new insights into the pro-tumorigenic action of lactic acid and its metabolism. These insights suggest an anti-tumor therapeutic strategy targeting the oncometabolite lactic acid, with the aim of improving the efficacy and clinical safety of tumor metabolism inhibitors. This review describes the current understanding of the multifunctional roles of tumor lactic acid, as well as therapeutic approaches targeting lactic acid metabolism, including lactate dehydrogenase and monocarboxylate transporters, for anti-cancer therapy.
AB - Tumor development is influenced by circulating metabolites and most tumors are exposed to substantially elevated levels of lactic acid and low levels of nutrients, such as glucose and glutamine. Tumor-derived lactic acid, the major circulating carbon metabolite, regulates energy metabolism and cancer cell signaling pathways, while also acting as an energy source and signaling molecule. Recent studies have yielded new insights into the pro-tumorigenic action of lactic acid and its metabolism. These insights suggest an anti-tumor therapeutic strategy targeting the oncometabolite lactic acid, with the aim of improving the efficacy and clinical safety of tumor metabolism inhibitors. This review describes the current understanding of the multifunctional roles of tumor lactic acid, as well as therapeutic approaches targeting lactic acid metabolism, including lactate dehydrogenase and monocarboxylate transporters, for anti-cancer therapy.
KW - Anti-tumor therapy
KW - Lactate dehydrogenases
KW - Lactic acid
KW - Lactic acid blocking strategy
KW - Monocarboxylate transporters
KW - Tumors
UR - http://www.scopus.com/inward/record.url?scp=85147290781&partnerID=8YFLogxK
U2 - 10.1007/s12272-023-01431-8
DO - 10.1007/s12272-023-01431-8
M3 - Review article
C2 - 36729274
AN - SCOPUS:85147290781
SN - 0253-6269
VL - 46
SP - 90
EP - 110
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 2
ER -